PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021

PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021

А virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- aBC) with the PIK3CA mutation using target drug alpelisib was held on April 23, 2021. Oncologists from France and Russia discussed the significance of the PIK3C...

Full description

Bibliographic Details
Main Author: Editorial Board
Format: Article
Language:Russian
Published: IP Habib O.N. 2021-08-01
Series:Современная онкология
Subjects:
hormone receptor positive her2-negative advanced breast cancer
pik3ca mutation
pi3k inhibitor
alpelisib
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/77894/58478

Internet

https://modernonco.orscience.ru/1815-1434/article/viewFile/77894/58478

Similar Items